MAM
BOLD

Meeder Asset Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Meeder Asset Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-505
Closed -$14K – 2529
2019
Q3 		$14K Sell
505
-221
-30% -$7.54K ﹤0.01% 1430
2019
Q2 		$27K Buy
726
+619
+579% +$23.8K ﹤0.01% 1138
2019
Q1 		$4K Sell
107
-184
-63% -$5.28K ﹤0.01% 1471
2018
Q4 		$6K Sell
291
-1,385
-83% -$35.7K ﹤0.01% 1391
2018
Q3 		$66K Buy
1,676
+1,548
+1,209% +$57.7K 0.01% 725
2018
Q2 		$4.89K Sell
128
-202
-61% -$7.48K ﹤0.01% 1282
2018
Q1 		$10K Buy
330
+41
+14% +$1.39K ﹤0.01% 1079
2017
Q4 		$9K Buy
289
+174
+151% +$4.78K ﹤0.01% 1173
2017
Q3 		$3K Sell
115
-16
-12% -$347 ﹤0.01% 1420
2017
Q2 		$3K Hold
131
– – ﹤0.01% 1363
2017
Q1 		$2K Buy
+131
New +$2.12K ﹤0.01% 1449

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Meeder Asset Management's BOLD Position: Q4 2019 in Review

Meeder Asset Management sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 505 shares — an estimated $14K sold.

Meeder Asset Management first reported a position in BOLD in Q1 2017 and held it in 11 quarters. The position peaked at $66K in Q3 2018. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

  • Meeder Asset Management reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • Meeder Asset Management sold 505 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $14K.
  • Meeder Asset Management first reported a position in Audentes Therapeutics, Inc in Q1 2017 and held it in 11 quarters.
  • Meeder Asset Management's Audentes Therapeutics, Inc position peaked at $66K in Q3 2018.
  • 188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Meeder Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.